Pseudomonas skin infection: Clinical features, epidemiology, and management

American Journal of Clinical Dermatology

Volumn 12, Issue 3, 2011, Pages 157-169

  Wu, Douglas C ^a   Chan, Wilson W ^a   Metelitsa, Andrei I ^a   Fiorillo, Loretta ^a   Lin, Andrew N ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Amikacin; Aminoglycosides; Antibacterial resistance; Antibacterials, therapeutic use; Aztreonam, therapeutic use; Bacteraemia, treatment; Beta lactams, therapeutic use; Cefepime, therapeutic use; Ceftazidime, therapeutic use; Ceftobiprole, therapeutic use; Ciprofloxacin, therapeutic use; Colistin, therapeutic use; Fluoroquinolones, therapeutic use; Folliculitis, treatment; Gentamicin, therapeutic use; Imipenem, therapeutic use; Meropenem, therapeutic use; Otitis externa, treatment; Piperacillin, therapeutic use; Polymixins, therapeutic use; Pseudomonal infections, diagnosis; Pseudomonal infections, epidemiology; Pseudomonal infections, pathogenesis; Pseudomonal infections, treatment; Research and development; Skin infections, treatment; therapeutic use; Ticarcillin, therapeutic use; Tobramycin, therapeutic use

Indexed keywords

AMIKACIN; AMOXICILLIN; ANTIINFECTIVE AGENT; AZTREONAM; CARBAPENEM; CARBENICILLIN; CEFEPIME; CEFTAZIDIME; CEFTOBIPROLE; CEFTRIAXONE; CIPROFLOXACIN; COLISTIN; DEXAMETHASONE; GENTAMICIN; HYPOCHLORITE SODIUM; IMIPENEM; MEROPENEM; PIPERACILLIN; SILVER NITRATE; SULFADIAZINE SILVER; TICARCILLIN; TOBRAMYCIN; UREIDOPENICILLIN DERIVATIVE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; ARTICLE; BACTEREMIA; BURN INFECTION; CLINICAL FEATURE; EAR INFECTION; EXTERNAL OTITIS; FOLLICULITIS; NECROTIZING FASCIITIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; SKIN INFECTION; SOFT TISSUE INFECTION; SUBCUTANEOUS NODULE;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; HUMANS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SKIN DISEASES, INFECTIOUS;

EID: 79953795730     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.2165/11539770-000000000-00000     Document Type: Article

References (139)

1. Blondel-Hill E, Henry DA, Speert DP. Pseudomonas. In:Murray PR, editor. Manual of clinical microbiology. 9th ed. Washington, DC:ASMPress, 2007: 734-48
2. Silvestre JF, Betlloch MI. Cutaneous manifestations due to Pseudomonas infection. Int J Dermatol 1999; 38 (6): 419-31 (Pubitemid 29287635)
3. Sato H, Okinaga K, Saito H. Role of pili in the pathogenesis of Pseudomonas aeruginosa burn infection. Microbiol Immunol 1988; 32 (2): 131-9 (Pubitemid 18096787)
4. Bejarano PA, Langeveld JP, Hudson BG, et al. Degradation of basement membranes by Pseudomonas aeruginosa elastase. Infect Immun 1989; 57 (12): 3783-7 (Pubitemid 20001248)
5. Ostroff RM, Vasil ML. Identification of a new phospholipase C activity by analysis of an insertional mutation in the hemolytic phospholipase C structural gene of Pseudomonas aeruginosa. J Bacteriol 1987; 169 (10): 4597-601 (Pubitemid 18052232)
6. Sokol PA. Surface expression of ferripyochelin-binding protein is required for virulence of Pseudomonas aeruginosa. Infect Immun 1987; 55 (9): 2021-5 (Pubitemid 17139276)
7. Pier GB, Goldberg JB. Pseudomonas aeruginosa A-band and B-band lipopolysaccharides. Infect Immun 1995; 63 (12): 4964-5
8. Nicas TI, Iglewski BH. Contribution of exoenzyme S to the virulence of Pseudomonas aeruginosa. Antibiot Chemother 1985; 36: 40-8
9. Henry RL, Mellis CM, Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol 1992; 12 (3): 158-61
10. Meluleni GJ, Grout M, Evans DJ, et al. Mucoid Pseudomonas aeruginosa growing in a biofilm in vitro are killed by opsonic antibodies to the mucoid exopolysaccharide capsule but not by antibodies produced during chronic lung infection in cystic fibrosis patients. J Immunol 1995; 155 (4): 2029-38
11. Pollack M. Pseudomonas aeruginosa. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 5th ed. Philadelphia (PA): Churchill Livingstone, 2000: 1760-6
12. Driscoll JA, Brody SL, Kollef MH. The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections. Drugs 2007; 67 (3): 351-68 (Pubitemid 46425550)
13. Wang MC, Liu CY, Shiao AS, et al. Ear problems in swimmers. J Chin Med Assoc 2005; 68 (8): 347-52
14. Chandrasekar PH, Rolston KV, Kannangara DW, et al. Hot tub-associated dermatitis due to Pseudomonas aeruginosa: case report and review of the literature. Arch Dermatol 1984; 120 (10): 1337-40 (Pubitemid 14041784)
15. Willcox MD. Pseudomonas aeruginosa infection and inflammation during contact lens wear: a review. Optom Vis Sci 2007; 84 (4): 273-8 (Pubitemid 46624851)
16. Speert DP, Campbell ME, Davidson AG, et al. Pseudomonas aeruginosa colonization of the gastrointestinal tract in patients with cystic fibrosis. J Infect Dis 1993; 167 (1): 226-9 (Pubitemid 23002865)
17. Vincent JL, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe: results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 1995; 274 (8): 639-44
18. Diekema DJ, Pfaller MA, Jones RN, et al. Survey of bloodstream infections due to gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997. Clin Infect Dis 1999; 29 (3): 595-607 (Pubitemid 29439960)
19. Foca M, Jakob K, Whittier S, et al. Endemic Pseudomonas aeruginosa infection in a neonatal intensive care unit. N Engl J Med 2000; 343 (10): 695-700
20. Moore M, Marcus MD. Green nails: the role of Candida (Syringospora, Monilia) and Pseudomonas aeruginosa. AMA Arch Derm Syphilol 1951; 64 (4): 499-505
21. Chernosky ME, Dukes CD. Green nails: importance of Pseudomonas aeruginosa in onychia. Arch Dermatol 1963; 88: 548-53
22. Maes M, Richert B, de la Brassinne M. Green nail syndrome or chloronychia. Rev Med Liege 2002; 57 (4): 233-5
23. Sakata S, Howard A. Pseudomonas chloronychia in a patient with nail psoriasis [letter]. Med J Aust 2007; 186 (8): 424 (Pubitemid 46691866)
24. Aste N, Atzori L, Zucca M, et al. Gram-negative bacterial toe web infection: a survey of 123 cases from the district of Cagliari, Italy. J Am Acad Dermatol 2001; 45 (4): 537-41 (Pubitemid 32917247)
25. Lestringant GG, Saarinen KA, Frossard PM, et al. Etiology of toe-web disease in Al-Ain, United Arab Emirates: bacteriological and mycological studies. East Mediterr Health J 2001; 7 (1-2): 38-45 (Pubitemid 33758520)
26. Karaca S, Kulac M, Cetinkaya Z, et al. Etiology of foot intertrigo in the District of Afyonkarahisar, Turkey: a bacteriologic and mycologic study. J Am Podiatr Med Assoc 2008; 98 (1): 42-4
27. Fangman W, Burton C. Hyperkeratotic rim of gram-negative toe web infections [letter]. Arch Dermatol 2005; 141 (5): 658 (Pubitemid 40656083)
28. Fowler Jr JF, Stege 3rd GC. Hot tub (Pseudomonas) folliculitis. J Ky Med Assoc 1990; 88 (2): 66-8
29. Zichichi L, Asta G, Noto G. Pseudomonas aeruginosa folliculitis after shower/bath exposure. Int J Dermatol 2000; 39 (4): 270-3 (Pubitemid 30260804)
30. Boni R, Nehrhoff B. Treatment of gram-negative folliculitis in patients with acne. Am J Clin Dermatol 2003; 4 (4): 273-6 (Pubitemid 36506431)
31. Hollyoak V, Allison D, Summers J. Pseudomonas aeruginosa wound infection associated with a nursing home's whirlpool bath. Commun Dis Rep CDR Rev 1995; 5 (7): R100-2
32. Fiorillo L, ZuckerM, Sawyer D, et al. The pseudomonas hot-foot syndrome. N Engl J Med 2001; 345 (5): 335-8 (Pubitemid 32703236)
33. Yu Y, Cheng AS, Wang L, et al. Hot tub folliculitis or hot hand-foot syndrome caused by Pseudomonas aeruginosa. J Am Acad Dermatol 2007; 57 (4): 596-600 (Pubitemid 47384918)
34. Prasad HK, Sreedharan S, Prasad HS, et al. Perichondritis of the auricle and its management. J Laryngol Otol 2007; 121 (6): 530-4 (Pubitemid 46800191)
35. Keene WE, Markum AC, Samadpour M. Outbreak of Pseudomonas aeruginosa infections caused by commercial piercing of upper ear cartilage. JAMA 2004; 291 (8): 981-5 (Pubitemid 38543756)
36. Handzel O, Halperin D. Necrotizing (malignant) external otitis. Am Fam Physician 2003; 68 (2): 309-12 (Pubitemid 36909395)
37. Shimizu T, Ishinaga H, Seno S, et al. Malignant external otitis: treatment with prolonged usage of antibiotics and Burow's solution. Auris Nasus Larynx 2005; 32 (4): 403-6 (Pubitemid 41423577)
38. Roland PS, Stroman DW. Microbiology of acute otitis externa. Laryngoscope 2002; 112 (7 Pt 1): 1166-77 (Pubitemid 34747209)
39. Kreger BE, Craven DE, Carling PC, et al. Gram-negative bacteremia: III. Reassessment of etiology, epidemiology and ecology in 612 patients. Am J Med 1980; 68 (3): 332-43 (Pubitemid 10130373)
40. Schlossberg D. Multiple erythematous nodules as a manifestation of Pseudomonas aeruginosa septicemia. Arch Dermatol 1980; 116 (4): 446-7 (Pubitemid 10147465)
41. Llistosella E, Ravella A, Moreno A, et al. Panniculitis in Pseudomonas aeruginosa septicemia. Acta Derm Venereol 1984; 64 (5): 447-9 (Pubitemid 14043151)
42. Bagel J, Grossman ME. Subcutaneous nodules in Pseudomonas sepsis. Am J Med 1986; 80 (3): 528-9 (Pubitemid 16098798)
43. Fleming MG, Milburn PB, Prose NS. Pseudomonas septicemia with nodules and bullae. Pediatr Dermatol 1987; 4 (1): 18-20 (Pubitemid 17077327)
44. Raffi F, Regnier B, Pichon F, et al. Pseudomonas aeruginosa sepsis presenting as peripheral subcutaneous nodules: report of 2 cases. Intensive Care Med 1988; 14 (4): 434-6
45. Campo RE, Ratzan KR, Melnick SJ. Subcutaneous nodules as a dermatologic manifestation of bacteremia due to Pseudomonas aeruginosa. South Med J 1994; 87 (2): 233-5 (Pubitemid 24074681)
46. Nieves DS, James WD. Painful red nodules of the legs: a manifestation of chronic infection with gram-negative organisms. J AmAcad Dermatol 1999; 41 (2 Pt 2): 319-21 (Pubitemid 29382005)
47. Teplitz C. Pathogenesis of Pseudomonas vasculitis and septic legions. Arch Pathol 1965; 80: 297-307
48. Sangeorzan JA, Bradley SF, Kauffman CA. Cutaneous manifestations of Pseudomonas infection in the acquired immunodeficiency syndrome. Arch Dermatol 1990; 126 (6): 832-3 (Pubitemid 20193812)
49. Bourelly PE, Grossman ME. Subcutaneous nodule as a manifestation of Pseudomonas sepsis in an immunocompromised host. Clin Infect Dis 1998; 26 (1): 188-9 (Pubitemid 28068180)
50. Asumang A, Goldsmith AL, Dryden M. Subcutaneous nodules with pseudomonas septicaemia in an immunocompetent patient. Anaesth Intensive Care 1999; 27 (2): 213-5 (Pubitemid 29164119)
51. Diaz-Valle D, Benitez del Castillo JM, Fernandex Acenero MJ, et al. Endogenous Pseudomonas endophthalmitis in an immunocompetent patient. Eur J Ophthalmol 2007; 17 (3): 461-3 (Pubitemid 47056312)
52. Aleman CT, Wallace ML, Blaylock WK, et al. Subcutaneous nodules caused by Pseudomonas aeruginosa without sepsis. Cutis 1999; 63 (3): 161-3
53. Mull CC, Scarfone RJ, Conway D. Ecthyma gangrenosum as a manifestation of Pseudomonas sepsis in a previously healthy child. Ann Emerg Med 2000; 36 (4): 383-7
54. Gencer S, Ozer S, Ege Gul A, et al. Ecthyma gangrenosum without bacteremia in a previously healthyman: a case report. JMed Case Reports 2008; 2 (1): 14
55. Zomorrodi A, Wald ER. Ecthyma gangrenosum: considerations in a previously healthy child. Pediatr Infect Dis J 2002; 21 (12): 1161-4 (Pubitemid 35463036)
56. Agarwal S, SharmaM, Mehndirata V. Solitary ecthyma gangrenosum (EG)- like lesion consequent to Candida albicans in a neonate. Indian J Pediatr 2007; 74 (6): 582-4 (Pubitemid 350104863)
57. Lobo I, Pinto A, Ferreira A, et al. Non-pseudomonal ecthyma gangrenosum present in diclofenac-induced agranulocytosis. Eur JDermatol 2008; 18 (3): 350-1 (Pubitemid 351821251)
58. Reich HL, Williams Fadeyi D, Naik NS, et al. Nonpseudomonal ecthyma gangrenosum. J Am Acad Dermatol 2004; 50 (5 Suppl.): S114-7 (Pubitemid 38580537)
59. Greene SL, Su WP, Muller SA. Ecthyma gangrenosum: report of clinical, histopathologic, and bacteriologic aspects of eight cases. J Am Acad Dermatol 1984; 11 (5 Pt 1): 781-7 (Pubitemid 15201318)
60. Ramar K, Hauer D, Potti A, et al. Ecthyma gangrenosum and chronic lymphocytic leukaemia [letter]. Lancet Infect Dis 2003; 3 (2): 113 (Pubitemid 36164208)
61. Chun WH, Kim YK, Kim LS, et al. Ecthyma gangrenosum associated with aplastic anemia. J Korean Med Sci 1996; 11 (1): 64-7
62. Kim EJ, Foad M, Travers R. Ecthyma gangrenosum in an AIDS patient with normal neutrophil count. J Am Acad Dermatol 1999; 1 (5 Pt 2): 840-1 (Pubitemid 29514002)
63. Solowski NL, Yao FB, Agarwal A, et al. Ecthyma gangrenosum: a rare cutaneous manifestation of a potentially fatal disease. Ann Otol Rhinol Laryngol 2004; 113 (6): 462-4 (Pubitemid 38781306)
64. Athappan G, Unnikrishnan A, Chandraprakasam S. Ecthyma gangrenosum: presentation in a normal neonate [letter]. Dermatol Online J 2008; 14 (2): 17
65. Gresik CM, Brewster LP, Abood G, et al. Ecthyma gangrenosum following toxic epidermal necrolysis syndrome in a 3-year-old boy:a survivable series of events. J Burn Care Res 2008; 29 (3): 555-8 (Pubitemid 351667944)
66. Downey DM, O'Bryan MC, Burdette SD, et al. Ecthyma gangrenosum in a patient with toxic epidermal necrolysis. J BurnCare Res 2007; 28 (1): 198-202 (Pubitemid 46087880)
67. Song WK, Kim YC, Park HJ, et al. Ecthyma gangrenosum without bacteraemia in a leukaemic patient. Clin Exp Dermatol 2001; 26 (5): 395-7 (Pubitemid 32863091)
68. Singh N, Devi M, Devi S. Ecthyma gangrenosum: a rare cutaneous manifestation caused by Pseudomonas aeruginosa without bacteremia in a leukemic patient. Indian J Dermatol Venereol Leprol 2005; 71 (2): 128-9 (Pubitemid 40976332)
69. Weinberg AN, Swartz MN. Gram-negative coccal and bacillary infections. In: Freedberg IM, Goldsmith LA, Katz S, et al., editors. Fitzpatrick's dermatology in general medicine. 6th ed. New York: McGraw-Hill, 2003: 1731-43
70. Inamadar AC, Palit A, Athankiar SB, et al. Periocular ecthyma gangrenosum in a diabetic patient [letter]. Br J Dermatol 2003; 148 (4): 821 (Pubitemid 36629767)
71. Weedon D. Bacterial and rickettsial infections. In: Weedon D, Strutton G, Rubin AI, editors. Skin pathology. Brisbane (QLD): Churchill Livingstone, 2002: 620
72. Carratala J, Roson B, Fernandez-Sabe N, et al. Factors associated with complications and mortality in adult patients hospitalized for infectious cellulitis. Eur J Clin Microbiol Infect Dis 2003; 22 (3): 151-7 (Pubitemid 36461364)
73. van der Meer JW, Alleman M, Boekhout M. Infectious episodes in severely granulocytopenic patients. Infection 1979; 7 (4): 171-5 (Pubitemid 10225925)
74. West SK, Joseph A, Foss AJ. Pseudomonas aeruginosa eyelid necrosis associated with Felty syndrome. Ophthal Plast Reconstr Surg 2008; 24 (4): 313-4
75. Falagas ME, Pappas VD, Michalopoulos A. Gangrenous, hemorrhagic, bullous cellulitis associated with Pseudomonas aeruginosa in a patient with Waldenstrom's macroglobulinemia. Infection 2007; 35 (5): 370-3 (Pubitemid 47502350)
76. Atzori L, Ferreli C, Zucca M, et al. Facial cellulitis associated with Pseudomonas aeruginosa complicating ophthalmic herpes zoster [letter]. Dermatol Online J 2004; 10 (2): 20
77. Habif TP. Images in clinical medicine: pseudomonas cellulitis [letter]. N Engl J Med 2005; 353 (2): e2
78. Poitelea C, Wearne MJ. Periocular necrotising fasciitis: a case report. Orbit 2005; 24 (3): 215-7 (Pubitemid 41243076)
79. Akamine M, Miyagi K, Uchihara T, et al. Necrotizing fasciitis caused by Pseudomonas aeruginosa. Intern Med 2008; 47 (6): 553-6 (Pubitemid 351663674)
80. Vaz I. Fournier gangrene. Trop Doct 2006; 36 (4): 203-4 (Pubitemid 44580916)
81. Martinelli G, Alessandrino EP, Bernasconi P, et al. Fournier's gangrene: a clinical presentation of necrotizing fasciitis after bone marrow transplantation. Bone Marrow Transplant 1998; 22 (10): 1023-6 (Pubitemid 28543067)
82. Cabrera H, Skoczdopole L, Marini M, et al. Necrotizing gangrene of the genitalia and perineum. Int J Dermatol 2002; 41 (12): 847-51 (Pubitemid 36075220)
83. Schlager T, Sadler J, Weber D, et al. Hospital-acquired infections in pediatric burn patients. South Med J 1994; 87 (4): 481-4 (Pubitemid 24118309)
84. Rastegar Lari A, Bahrami Honar H, Alaghehbandan R. Pseudomonas infections in Tohid Burn Center, Iran. Burns 1998; 24 (7): 637-41 (Pubitemid 29002582)
85. Santucci SG, Gobara S, Santos CR, et al. Infections in a burn intensive care unit: experience of seven years. J Hosp Infect 2003; 53 (1): 6-13 (Pubitemid 38004381)
86. Hsueh PR, Teng LJ, Yang PC, et al. Persistence of a multidrug-resistant Pseudomonas aeruginosa clone in an intensive care burn unit. J Clin Microbiol 1998; 36 (5): 1347-51
87. Agnihotri N, Gupta V, Joshi RM. Aerobic bacterial isolates from burn wound infections and their antibiograms: a five-year study. Burns 2004; 30 (3): 241-3 (Pubitemid 38479902)
88. Ozkurt Z, Ertek M, Erol S, et al. The risk factors for acquisition of imipenemresistant Pseudomonas aeruginosa in the burn unit. Burns 2005; 31 (7): 870-3 (Pubitemid 41394144)
89. Wibbenmeyer L, Danks R, Faucher L, et al. Prospective analysis of nosocomial infection rates, antibiotic use, and patterns of resistance in a burn population. J Burn Care Res 2006; 27 (2): 152-60 (Pubitemid 43970315)
90. Meynard JL, Barbut F, Guiguet M, et al. Pseudomonas aeruginosa infection in human immunodeficiency virus infected patients. J Infect 1999; 38 (3): 176-81 (Pubitemid 29317387)
91. Berger TG, Kaveh S, Becker D, et al. Cutaneous manifestations of Pseudomonas infections in AIDS. J Am Acad Dermatol 1995; 32 (2 Pt 1): 279-80
92. Meissner M, Spieth K, Wolter M, et al. Cutaneous botryomycosis: a rarely diagnosed bacterial infection of the skin. Hautarzt 2007; 58 (11): 966-8
93. Picou K, Batres E, JarrattM. Botryomycosis: a bacterial cause of mycetoma. Arch Dermatol 1979; 115 (5): 609-10
94. Bishop GF, Greer KE, Horwitz DA. Pseudomonas botryomycosis. Arch Dermatol 1976; 112 (11): 1568-70
95. Conti-Diaz IA, Almeida EA, Rondan M, et al. Cutaneous botryomycosis: report of the two first Uruguayan cases. Rev Inst Med Trop Sao Paulo 1996; 38 (5): 375-8 (Pubitemid 127541827)
96. Petrozzi JW, Erlich A. Pseudomonal balanitis. Arch Dermatol 1977; 113 (7): 952-3 (Pubitemid 8146841)
97. Manian FA, Alford RH. Nosocomial infectious balanoposthitis in neutropenic patients. South Med J 1987; 80 (7): 909-11 (Pubitemid 17139806)
98. Egan CA, O'Reilly MA, Meadows KP, et al. Relapsing Henoch-Schonlein purpura associated with Pseudomonas aeruginosa pyelonephritis. J Am Acad Dermatol 2000; 42 (2 Pt 2): 381-3 (Pubitemid 30463696)
99. Unal S, Ersoz G, Demirkan F, et al. Analysis of skin-graft loss due to infection: infection-related graft loss. Ann Plast Surg 2005; 55 (1): 102-6 (Pubitemid 40884808)
100. Hanberger H, Garcia-Rodriguez JA, Gobernado M, et al. Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries: French and Portuguese ICU Study Groups. JAMA 1999; 281 (1): 67-71 (Pubitemid 29025102)
101. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 2002; 34 (5): 634-40 (Pubitemid 34165326)
102. Bonomo RA, Szabo D.Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis 2006; 43 Suppl. 2: S49-56 (Pubitemid 44267140)
103. Rello J, Ausina V, Ricart M, et al. Impact of previous antimicrobial therapy on the etiology and outcome of ventilator-associated pneumonia. Chest 1993; 104 (4): 1230-5 (Pubitemid 23306084)
104. Neuhauser MM, Weinstein RA, Rydman R, et al. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 2003; 289 (7): 885-8 (Pubitemid 37430348)
105. Valencia IC,Kirsner RS,Kerdel FA. Microbiologic evaluation of skinwounds: alarming trend toward antibiotic resistance in an inpatient dermatology service during a 10-year period. J Am Acad Dermatol 2004; 50 (6): 845-9 (Pubitemid 38685761)
106. Troillet N, Samore MH, Carmeli Y. Imipenem-resistant Pseudomonas aeruginosa: risk factors and antibiotic susceptibility patterns. Clin Infect Dis 1997; 25 (5): 1094-8 (Pubitemid 27513193)
107. Rubinstein E, Lode H, Grassi C. Ceftazidime monotherapy vs. ceftriaxone/ tobramycin for serious hospital-acquired gram-negative infections: Antibiotic Study Group. Clin Infect Dis 1995; 20 (5): 1217-28
108. Fink MP, Snydman DR, Niederman MS, et al. Treatment of severe pneumonia in hospitalized patients: results of amulticenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group. Antimicrob Agents Chemother 1994; 38 (3): 547-57 (Pubitemid 24072247)
109. Norrby SR, Finch RG, Glauser M. Monotherapy in serious hospital-acquired infections: a clinical trial of ceftazidime versus imipenem/cilastatin. European Study Group. J Antimicrob Chemother 1993; 31 (6): 927-37 (Pubitemid 23218155)
110. Carmeli Y, Troillet N, Eliopoulos GM, et al. Emergence of antibioticresistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999; 43 (6): 1379-82 (Pubitemid 29259329)
111. Giamarellou H. Prescribing guidelines for severe Pseudomonas infections. J Antimicrob Chemother 2002; 49 (2): 229-33 (Pubitemid 34162610)
112. Giamarellou H, Antoniadou A. Antipseudomonal antibiotics. Med Clin North Am 2001; 85 (1): 19-42, v (Pubitemid 32038721)
113. Sader HS, Fritsche TR, Jones RN. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003). Diagn Microbiol Infect Dis 2005; 52 (3): 265-73 (Pubitemid 41133554)
114. Giamarellos-Bourboulis EJ, Grecka P, Giamarellou H. In-vitro interactions of DX-8739, a new carbapenem, meropenem and imipenem with amikacin against multiresistant Pseudomonas aeruginosa. J Antimicrob Chemother 1996; 38 (2): 287-91 (Pubitemid 26302591)
115. Giamarellou H, Petrikkos G. Ciprofloxacin interactions with imipenem and amikacin against multiresistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 1987; 31 (6): 959-61 (Pubitemid 17084063)
116. Giamarellou H, Zissis NP, Tagari G, et al. In vitro synergistic activities of aminoglycosides and new beta-lactams against multiresistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 1984; 25 (4): 534-6 (Pubitemid 14129626)
117. Bodey GP, Jadeja L, Elting L. Pseudomonas bacteremia: retrospective analysis of 410 episodes. Arch Intern Med 1985; 145 (9): 1621-9 (Pubitemid 16258204)
118. Michea-Hamzehpour M, Pechere JC, Marchou B, et al. Combination therapy: a way to limit emergence of resistance? Am JMed 1986; 80 (6B): 138-42 (Pubitemid 16036778)
119. Michea-Hamzehpour M, Auckenthaler R, Regamey P, et al. Resistance occurring after fluoroquinolone therapy of experimental Pseudomonas aeruginosa peritonitis. Antimicrob Agents Chemother 1987; 31 (11): 1803-8 (Pubitemid 17157648)
120. Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004; 4 (8): 519-27 (Pubitemid 39077923)
121. Paul M, Leibovici L. Combination antibiotic therapy for Pseudomonas aeruginosa bacteraemia. Lancet Infect Dis 2005; 5 (4): 192-13; discussion 193-4
122. Chamot E, Boffi El Amari E, Rohner P, et al. Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2003; 47 (9): 2756-64 (Pubitemid 37040244)
123. Chatzinikolaou I, Abi-Said D, Bodey GP, et al. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: retrospective analysis of 245 episodes. Arch Intern Med 2000; 160 (4): 501-9 (Pubitemid 30112273)
124. Leibovici L, Paul M, Poznanski O, et al. Monotherapy versus beta-lactamaminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study. Antimicrob Agents Chemother 1997; 41 (5): 1127-33 (Pubitemid 27194197)
125. Siegman-Igra Y, Ravona R, Primerman H, et al. Pseudomonas aeruginosa bacteremia: an analysis of 123 episodes, with particular emphasis on the effect of antibiotic therapy. Int J Infect Dis 1998; 2 (4): 211-5 (Pubitemid 28422099)
126. Westmoreland TA, Ross EV, Yeager JK. Pseudomonas toe web infections. Cutis 1992; 49 (3): 185-6
127. Gupta AK, Skinner AR, Cooper EA. Evaluation of the efficacy of ciclopirox 0.77% gel in the treatment of tinea pedis interdigitalis (dermatophytosis complex) in a randomized, double-blind, placebo-controlled trial. Int J Dermatol 2005; 44 (7): 590-3 (Pubitemid 40960124)
128. Carfrae MJ, Kesser BW. Malignant otitis externa. Otolaryngol Clin North Am 2008; 41 (3): 537-49
129. Johnson MP, Ramphal R. Malignant external otitis: report on therapy with ceftazidime and review of therapy and prognosis. Rev Infect Dis 1990; 12 (2): 173-80 (Pubitemid 20118643)
130. Bernstein JM, Holland NJ, Porter GC, et al. Resistance of Pseudomonas to ciprofloxacin: implications for the treatment of malignant otitis externa. J Laryngol Otol 2007; 121 (2): 118-23
131. Pruitt Jr BA, McManus AT, Kim SH, et al. Burn wound infections: current status. World J Surg 1998; 22 (2): 135-45 (Pubitemid 28065179)
132. Wang CY, Jerng JS, Chen KY, et al. Pandrug-resistant Pseudomonas aeruginosa among hospitalised patients: clinical features, risk-factors and outcomes. Clin Microbiol Infect 2006; 12 (1): 63-8 (Pubitemid 43372241)
133. Reinert RR, Low DE, Rossi F, et al. Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline. J Antimicrob Chemother 2007; 60 (5): 1018-29 (Pubitemid 47617749)
134. Fritsche TR, Sader HS, Jones RN. Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004). Diagn Microbiol Infect Dis 2007; 58 (1): 19-26 (Pubitemid 46694276)
135. Burkhardt O,DerendorfH,Welte T. Ertapenem: the new carbapenem 5 years after first FDA licensing for clinical practice. Expert Opin Pharmacother 2007; 8 (2): 237-56 (Pubitemid 46206625)
136. RossoliniGM. Redesigning beta-lactams to combat resistance: summary and conclusions. Clin Microbiol Infect 2007; 13 Suppl. 2: 30-3 (Pubitemid 46711387)
137. Mangoni ML, Maisetta G, Di Luca M, et al. Comparative analysis of the bactericidal activities of amphibian peptide analogues against multidrugresistant nosocomial bacterial strains. Antimicrob Agents Chemother 2008; 52 (1): 85-91
138. Kipnis E, Sawa T,Wiener-Kronish J. Targeting mechanisms of Pseudomonas aeruginosa pathogenesis. Med Mal Infect 2006; 36 (2): 78-91 (Pubitemid 43294628)
139. Larson EL, Cimiotti JP, Haas J, et al. Gram-negative bacilli associated with catheter-associated and non-catheter-associated bloodstream infections and hand carriage by healthcare workers in neonatal intensive care units. Pediatr Crit Care Med 2005; 6 (4): 457-61 (Pubitemid 40980828)